XHKG
1858
Market cap569mUSD
Oct 09, Last price
7.33HKD
1D
-2.40%
1Q
-16.04%
Jan 2017
190.87%
IPO
-51.59%
Name
Beijing Chunlizhengda Medical Instruments Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Beijing Chunlizhengda Medical Instruments Co., Ltd. functions as a prominent entity within the orthopedic medical device industry, dedicated to the development, manufacturing, and distribution of surgical implants, instruments, and associated medical supplies throughout the People's Republic of China. Its core product range features implantable orthopedic solutions, specifically comprising joint prostheses and spinal treatment products. The company predominantly distributes its merchandise via an expansive network of distributors, through original design manufacturing (ODM) and original equipment manufacturing (OEM) partnerships under the 'Chunli' label, and by direct sales to healthcare institutions. Beyond its domestic operations, the firm also engages in exporting its products to various countries globally. Established in 1998, its corporate headquarters are situated in Beijing, China.
Key people
Yumei Li
Chief Financial Officer · since 2018
Chunsheng Shi
General Manager · since 2022
Xiwang Li
Deputy General Manager · since 2020
Zhiyong Zhai
Deputy General Manager · since 2020
Fengbao Xie
Secretary of the Board, Director · since 2024
Chunbao Shi
Chief Engineer, Director · since 2022
Wenling Shi
Chairman of the Board · since 2023
Xin Wang
Director
Shujun Yue
Deputy General Manager, Director · since 2014
Jie Weng
Independent Director
Independent Director
Independent Director · since 2024
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||